Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2007

Merck KGaA and Nano Terra Embark on Nanotechnology Alliance

  • Merck KGaA and Nano Terra will develop solutions to create new physical properties in specialty chemicals, currently manufactured and sold by Merck.

    These solutions will allow Merck’s materials to be used with greater precision and control and allow for new applications at reduced economic levels never before possible, according to the companies.

    The new properties will be made through nanoscale, molecular fabrication methods. Nano Terra says it pioneered these techniques along with its co-founder, George M. Whitesides of Harvard University.

    The development work will be done primarily at Nano Terra’s lab facilities in Cambridge. Local support for the alliance will be provided by EMD Chemicals, Merck’s North American affiliate.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »